Sugi Predict

Sugi Predict / Compounds / SCHEMBL841624

SCHEMBL841624

SCHEMBL841624

O=C1C=CC(=O)N1CCCCON1C(=O)CCC1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 7/20 0.55
▸ FAAH O00519 4/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ LMNA P02545 2/20 0.53
▸ HPGD P15428 2/20 0.53
▸ HSP90AA1 P07900 1/20 0.53
▸ TLR9 Q9NR96 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ TP53 P04637 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ XBP1 P17861 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ GPR35 Q9HC97 1/20 0.53
▸ GPR55 Q9Y2T6 1/20 0.53
▸ ALOX12 P18054 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL946089 0.98 MGLL (0.57) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL594145 0.98 MGLL (0.57) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL28704923 0.95 MGLL (0.52) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL4882564 0.87 MGLL (0.53) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL29270039 0.81 MGLL (0.67) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL18522835 0.77 ALOX12 (0.41) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL7093768 0.75 MGLL (0.73) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL18918259 0.74 PTGS1 (0.53) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL155748 0.74 MGLL (1.00) MGLLFAAHSMN1; SMN2LMNAHPGD
SCHEMBL19718345 0.74 MGLL (0.50) MGLLFAAHSMN1; SMN2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114728078-B Extracellular vesicles linked to molecules and uses thereof 隆萨销售股份公司 2025-05-16 — — CN disclosed
CN-119948163-A CEBP/beta targeted extracellular vesicle-ASO constructs 隆萨销售股份有限公司 2025-05-06 — — CN disclosed
CN-119855597-A Methods of using STAT 6-targeted extracellular vesicles-ASOs 隆萨销售股份有限公司 2025-04-18 — — CN disclosed
CN-113747925-B Extracellular vesicle conjugates and uses thereof 隆萨销售股份公司 2024-10-15 — — CN disclosed
US-11992527-B2 Extracellular vesicles for vaccine delivery LONZA SALES AG (CH) 2024-05-28 — — US disclosed
US-20240167036-A1 EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST LONZA SALES AG (CH) 2024-05-23 — — US disclosed
US-20240108747-A1 EXTRACELLULAR VESICLE CONJUGATES AND USES THEREOF LONZA SALES AG (CH) 2024-04-04 — — US disclosed
WO-2024026345-A2 EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA LONZA SALES AG (CH) 2024-02-01 — — WO disclosed
WO-2024006813-A2 METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 LONZA SALES AG (CH) 2024-01-04 — — WO disclosed
CN-117157093-A Extracellular vesicle-NLRP 3 antagonists 隆萨销售股份有限公司 2023-12-01 — — CN disclosed
CN-101981185-B Double-stranded lipid-modified RNA with strong RNA interference effect NAT INST OF ADVANCED IND SCIEN (JP) 2013-07-10 — — CN disclosed
CN-101918554-B Complex of polysaccharide and double-stranded RNA NAT INST OF ADVANCED IND SCIEN 2013-07-03 — — CN disclosed
US-8143413-B2 Polycationized phospholipid derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-03-27 — — US disclosed
CN-101981185-A Double-stranded lipid-modified RNA with strong RNA interference effect NAT INST OF ADVANCED IND SCIEN (JP) 2011-02-23 — — CN disclosed
US-20110008814-A1 Enzyme Immunoassay Using Enzyme-Labeled Antibody KIKKOMAN CORPORATION (JP) 2011-01-13 — — US disclosed
CN-101918554-A Complex of polysaccharide and double-stranded RNA NAT INST OF ADVANCED IND SCIEN 2010-12-15 — — CN disclosed
US-20100298411-A1 LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY 2010-11-25 — — US disclosed
EP-2217284-A2 LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT National Institute of Advanced Industrial Science And Technology (JP) 2010-08-18 — — EP disclosed
US-20100094020-A1 POLYCATIONIZED PHOSPHOLIPID DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-04-15 — — US disclosed
WO-2009054551-A2 LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 2009-04-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240167036-A1 EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST NLRP3, MTREX, NLRP1 MGLL 3909/4885FAAH 4278/4885SMN1; SMN2 164/4885
US-20100298411-A1 LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT NSUN3, NSUN2, RNASE1 MGLL 195/4885FAAH 1896/4885SMN1; SMN2 1568/4885
US-11992527-B2 Extracellular vesicles for vaccine delivery HAVCR2, CD74, HMGB1 MGLL 1740/4885FAAH 4498/4885SMN1; SMN2 635/4885
US-20240108747-A1 EXTRACELLULAR VESICLE CONJUGATES AND USES THEREOF EXOSC5, EXOSC10, EXOSC4 MGLL 4065/4885FAAH 4535/4885SMN1; SMN2 1401/4885
US-20100094020-A1 POLYCATIONIZED PHOSPHOLIPID DERIVATIVES PHOSPHO1, PLTP, PTDSS2 MGLL 182/4885FAAH 1815/4885SMN1; SMN2 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.